Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma

Japanese Journal of Clinical Oncology

Volumn 44, Issue 9, 2014, Pages 872-875

  Sato, Yuki ^a   Fujimoto, Daichi ^a   Shibata, Yumi ^a   Seo, Ryutaro ^a   Suginoshita, Yoshiki ^a   Imai, Yukihiro ^a   Tomii, Keisuke ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

Anaplastic lymphoma kinase; Crizotinib; Drug induced liver toxicity; Fulminant hepatitis; Tyrosine kinase inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CRIZOTINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ALKALINE PHOSPHATASE; BILIRUBIN; FOSPHENYTOIN SODIUM; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS C ANTIBODY; MIDAZOLAM; PREDNISOLONE; RABEPRAZOLE; SITAGLIPTIN; STEROID; THYROID TRANSCRIPTION FACTOR 1;

BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CASE REPORT; CHEMISTRY; DRUG-INDUCED LIVER INJURY; ENZYMOLOGY; FATALITY; FEMALE; HUMAN; LUNG NEOPLASMS; MIDDLE AGED; RISK FACTOR; ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOPSY; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; BLURRED VISION; BONE METASTASIS; BRAIN ADENOCARCINOMA; BRAIN CANCER; BRAIN HEMORRHAGE; CANCER DIAGNOSIS; CANCER STAGING; CLAVICLE BONE METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS DISORDER; CONTINUOUS HEMODIAFILTRATION; CONVULSION; CRANIOTOMY; DERMATOMYOSITIS; DIABETES MELLITUS; DRUG PULSE THERAPY; EPIGASTRIC PAIN; FLUORESCENCE IN SITU HYBRIDIZATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE REARRANGEMENT; HEADACHE; HELIOTROPE RASH; HEPATIC ENCEPHALOPATHY; HEPATITIS; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACRANIAL HEMORRHAGIC MASS; JAUNDICE; LOW DRUG DOSE; LUNG ADENOCARCINOMA; MALAISE; MEDIASTINUM LYMPHADENOPATHY; MENTAL DETERIORATION; MYALGIA; PATIENT HISTORY OF THERAPY; PHYSICAL EXAMINATION; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; PROTHROMBIN TIME; RASH; SEVERE HEPATIC IMPAIRMENT; STEROID INDUCED DIABETES MELLITUS; THORAX RADIOGRAPHY; TREATMENT DURATION; VOMITING; WHOLE BODY CT;

ALANINE TRANSAMINASE; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG-INDUCED LIVER INJURY; FATAL OUTCOME; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RISK FACTORS;

EID: 84906874546     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyu086     Document Type: Article

References (18)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-9.
3. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:23-94.
4. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-12.
5. Ripault MP, Pinzani V, Fayolle V, et al. Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose. Clin Res Hepatol Gastroenterol 2013;37:e21-3.
6. Roberts PJ. Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics 2013;7:91-101.
7. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013;63:249-79.
8. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7.
9. Sugawara K, Nakayama N, Satoshi M. Acute liver failure in Japan: definition, classification, and prediction the outcome. J Gastroenterol 2012;47:849-61.
10. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30.
11. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010;52:730-42.
12. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatol 1997;26:664-9.
13. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-9.
14. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008;66:758-66.
15. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004;38:S44-8.
16. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008;14:6774-85.
17. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009;29:337-47.
18. Curran MP. Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs 2012;72:99-107.